Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass balance study of [14C]-IPN60250 in healthy adults
NL-OMON60420Phase 1Completed
- Sponsor
- Ipsen
- Start
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of A3907 in Primary Sclerosing Cholangitis (PSC), sponsored by Ipsen. Primary endpoint: Primary endpoint(s). Started Feb 2025; status: completed.
02
Drugs
A3907
03
Conditions
Primary Sclerosing Cholangitis (PSC)
Beyond the preview
Go deeper on NL-OMON60420.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60420.